SSS International Clinical Research
Mid-sized, full-service clinical research organization operating across Europe and North America. Provides end-to-end clinical development services (Phases I–IV) and functional service provider (FSP) resourcing with therapeutic area capabilities across oncology, neuroscience, cardiology, endocrine-metabolic, gastroenterology, dermatology, ophthalmology, women’s health, rare diseases and medical devices. Demonstrated capabilities include accelerated study start-up, recruitment performance, multi-jurisdiction regulatory navigation, centralized data operations and an established business intelligence capability. Leadership includes dedicated heads for project management, regulatory/site activation, data management, biostatistics and business intelligence.
Industries
Nr. of Employees
medium (51-250)
SSS International Clinical Research
Products
Full Service Phase I-IV
Comprehensive clinical trial services spanning Phase I to Phase IV development.
Functional Service Provision
Flexible functional service provision (FSP) and clinical staffing augmentation services for clinical trials.
Real World Research
Real-world evidence (RWE) and post-marketing clinical research services.
Full Service Phase I-IV
Comprehensive clinical trial services spanning Phase I to Phase IV development.
Functional Service Provision
Flexible functional service provision (FSP) and clinical staffing augmentation services for clinical trials.
Real World Research
Real-world evidence (RWE) and post-marketing clinical research services.
Services
End-to-end clinical development support across Phases I–IV and medical device studies including regulatory strategy, monitoring, data management, biostatistics, medical writing, pharmacovigilance and project management.
Regulatory strategy, clinical trial applications, local regulatory and ethics submissions, management of regulatory communications and preparation of amendments across multiple jurisdictions.
Feasibility assessments, site qualification, initiation, monitoring, close-out, remote monitoring and audit/inspection support.
Project planning, study tracking, KPI monitoring, vendor management and centralized project data using a CTMS.
CRF and database design, data validation, CDISC/SDTM mapping and ePRO implementation for regulatory submissions.
Study design input, SAP development, sample size calculations, randomisation, interim analyses and PK/PD modelling.
End-to-end clinical development support across Phases I–IV and medical device studies including regulatory strategy, monitoring, data management, biostatistics, medical writing, pharmacovigilance and project management.
Regulatory strategy, clinical trial applications, local regulatory and ethics submissions, management of regulatory communications and preparation of amendments across multiple jurisdictions.
Feasibility assessments, site qualification, initiation, monitoring, close-out, remote monitoring and audit/inspection support.
Project planning, study tracking, KPI monitoring, vendor management and centralized project data using a CTMS.
CRF and database design, data validation, CDISC/SDTM mapping and ePRO implementation for regulatory submissions.
Study design input, SAP development, sample size calculations, randomisation, interim analyses and PK/PD modelling.
Expertise Areas
- Clinical trial management
- Regulatory compliance and ethics submissions (multi-country)
- Data management and CDISC/SDTM implementation
- Biostatistics and statistical programming
Key Technologies
- Clinical trial management systems (CTMS)
- Electronic data capture (EDC) systems
- ePRO platforms
- eTMF systems
News & Updates
Appointment of Paul Miller as Chief Commercial Officer announced on company news page.
Announcement of Pavle Vukojević as Chief Medical Officer, effective immediately.
Interview discussing early experiences with the Clinical Trials Information System (CTIS) and its impact on EU clinical research practice.
Rescued a Phase III ACS study by recruiting 649 patients at 57 sites in five countries and completing the study four months early.
Completed 111% of target recruitment five months early for a Phase III oncology trial with 30 sites.
Enrolled the first EU patient for a global rare disease clinical trial and achieved full recruitment in a paediatric rare disease study.
Appointment of Paul Miller as Chief Commercial Officer announced on company news page.
Announcement of Pavle Vukojević as Chief Medical Officer, effective immediately.
Interview discussing early experiences with the Clinical Trials Information System (CTIS) and its impact on EU clinical research practice.
Rescued a Phase III ACS study by recruiting 649 patients at 57 sites in five countries and completing the study four months early.
Completed 111% of target recruitment five months early for a Phase III oncology trial with 30 sites.
Enrolled the first EU patient for a global rare disease clinical trial and achieved full recruitment in a paediatric rare disease study.